Albuminuria is not an aggravating factor in experimental focal glomerulosclerosis and hyalinosis.
It is widely known that the severity of glomerular sclerosis is proportional to the degree and chronicity of proteinuria and that the degenerative changes of glomerular epithelial cells that are associated with overflow albuminuria can be experimentally induced by the injection of large quantities of heterologous albumin. Such evidence suggests that autologous albuminuria per se may have a harmful effect on the kidneys. To examine the cause and effect relationship between renal lesions and albuminuria, we produced Adriamycin-induced experimental focal glomerular sclerosis in Nagase analbuminemic (NA) rats and control Sprague-Dawley (SD) rats and observed both the renal functional and histologic changes for 20 weeks. At week 4 after injection of Adriamycin glomerular epithelial lesions including foot process fusion were similarly revealed by an electron microscopic study in both groups in spite of the presence of a large difference in the amount of proteinuria (SD rats: 491 +/- 84 mg/day, NA rats: 43 +/- 30 mg/day) and albuminuria (SD rats: 383 +/- 73 mg/day, NA rats: 2 +/- 1 mg/day). At week 20, a light microscopic study showed the same degree of glomerular sclerosis and hyalinosis and tubulointerstitial changes associated with a decrease in inulin clearance in both groups. The increased glomerular accumulation of immunoglobulin M or complement 3 and glomerular trapping of aggregated human immunoglobulin G were also similar between the SD and NA groups. In summary, renal destruction of Adriamycin-nephropathy was not dependent on the degree of albuminuria. These results suggest that albuminuria is not an aggravating factor in focal glomerulosclerosis.
Second Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
S
S
Okuda
N
N
Oochi
M
M
Wakisaka
H
H
Kanai
K
K
Tamaki
S
S
Nagase
K
K
Onoyama
M
M
Fujishima
D000418:Albumins / Q000493:pharmacokinetics; D000419:Albuminuria / Q000150:complications* / Q000378:metabolism; D000818:Animals; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004591:Electrophoresis, Polyacrylamide Gel; D005923:Glomerulosclerosis, Focal Segmental / Q000139:chemically induced / Q000150:complications* / Q000378:metabolism; D006818:Hyalin / Q000378:metabolism*; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007267:Injections; D007444:Inulin / Q000493:pharmacokinetics; D007668:Kidney / Q000737:chemistry / Q000378:metabolism / Q000473:pathology; D008297:Male; D008854:Microscopy, Electron; D011507:Proteinuria / Q000150:complications / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D000418:Albumins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D004317:Doxorubicin; D007444:Inulin